A US security consulting firm has warned that the worldwide epidemic of counterfeit pharmaceuticals could be the "world's next 9/11," a reference to the terrorist attacks on September 11, 2001 in New York City and Washington DC. The Global Piracy & Counterfeiting Consultants is part of the Americas Watchdog group.
In a statement, the group said: "the USA, Europe, Japan or Australia are going to get hit sooner or later, with shipments of counterfeit pharmaceutical intentionally or unintentionally designed to kill people." The GP-CC has issued a simple piece of advice to would-be Internet drug purchasers: "consumers should not purchase drugs, pharmaceuticals, medicine of any type on the Internet, unless they are 100% certain it is real."
The problem is that there are several reasons for patients to go on-line to find drugs, the security consultant argues. These include: the belief that on-line drugs are cheaper; unwillingness to approach a physician to obtain a prescription (especially in the case of erectile dysfunction, a significant market for counterfeiters); patients who have been refused a prescription by their physician; and uninsured or low-income patients for whom the cost of a physician's consultation is prohibitive.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze